Cargando…
It’s all in the name: why exposure therapy could benefit from a new one
Exposure therapy for anxiety and related disorders is the psychological intervention with the strongest support for its efficacy and effectiveness to date. Yet, it is the least used evidence-based intervention in routine clinical practice, with a long-acknowledged public relations problem. Despite a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161762/ https://www.ncbi.nlm.nih.gov/pubmed/35669210 http://dx.doi.org/10.1007/s12144-022-03286-6 |
_version_ | 1784719552896040960 |
---|---|
author | Becker-Haimes, Emily M. Stewart, Rebecca E. Frank, Hannah E. |
author_facet | Becker-Haimes, Emily M. Stewart, Rebecca E. Frank, Hannah E. |
author_sort | Becker-Haimes, Emily M. |
collection | PubMed |
description | Exposure therapy for anxiety and related disorders is the psychological intervention with the strongest support for its efficacy and effectiveness to date. Yet, it is the least used evidence-based intervention in routine clinical practice, with a long-acknowledged public relations problem. Despite a wealth of research aimed at improving uptake of exposure, exposure’s marketing and branding remains an untapped target. We first introduce principles from the marketing literature to propose that the field take steps toward a rebranding and repackaging of exposure therapy to support efforts to implement it widely. Second, we present preliminary data on clinician preferences for the use of alternative terminology developed to be more palatable and marketable - “Supported Approach of Feared Experiences – Cognitive Behavioral Therapy (SAFE-CBT)” - compared to traditional terminology. This initial survey indicated that most clinicians preferred use of the SAFE-CBT term when talking to patients, whereas only a minority preferred it for use among training clinicians. We conclude by discussing implications of these results for future efforts to implement exposure therapy more widely and set an agenda for future research in this space. |
format | Online Article Text |
id | pubmed-9161762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-91617622022-06-02 It’s all in the name: why exposure therapy could benefit from a new one Becker-Haimes, Emily M. Stewart, Rebecca E. Frank, Hannah E. Curr Psychol Article Exposure therapy for anxiety and related disorders is the psychological intervention with the strongest support for its efficacy and effectiveness to date. Yet, it is the least used evidence-based intervention in routine clinical practice, with a long-acknowledged public relations problem. Despite a wealth of research aimed at improving uptake of exposure, exposure’s marketing and branding remains an untapped target. We first introduce principles from the marketing literature to propose that the field take steps toward a rebranding and repackaging of exposure therapy to support efforts to implement it widely. Second, we present preliminary data on clinician preferences for the use of alternative terminology developed to be more palatable and marketable - “Supported Approach of Feared Experiences – Cognitive Behavioral Therapy (SAFE-CBT)” - compared to traditional terminology. This initial survey indicated that most clinicians preferred use of the SAFE-CBT term when talking to patients, whereas only a minority preferred it for use among training clinicians. We conclude by discussing implications of these results for future efforts to implement exposure therapy more widely and set an agenda for future research in this space. Springer US 2022-06-02 /pmc/articles/PMC9161762/ /pubmed/35669210 http://dx.doi.org/10.1007/s12144-022-03286-6 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Becker-Haimes, Emily M. Stewart, Rebecca E. Frank, Hannah E. It’s all in the name: why exposure therapy could benefit from a new one |
title | It’s all in the name: why exposure therapy could benefit from a new one |
title_full | It’s all in the name: why exposure therapy could benefit from a new one |
title_fullStr | It’s all in the name: why exposure therapy could benefit from a new one |
title_full_unstemmed | It’s all in the name: why exposure therapy could benefit from a new one |
title_short | It’s all in the name: why exposure therapy could benefit from a new one |
title_sort | it’s all in the name: why exposure therapy could benefit from a new one |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161762/ https://www.ncbi.nlm.nih.gov/pubmed/35669210 http://dx.doi.org/10.1007/s12144-022-03286-6 |
work_keys_str_mv | AT beckerhaimesemilym itsallinthenamewhyexposuretherapycouldbenefitfromanewone AT stewartrebeccae itsallinthenamewhyexposuretherapycouldbenefitfromanewone AT frankhannahe itsallinthenamewhyexposuretherapycouldbenefitfromanewone |